The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants by Blann, Andrew D & Khoo, Chee W
© 2009 Blann and Khoo, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2009:5 693–704
Vascular Health and Risk Management
693
R e V i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
The prevention and treatment of venous 
thromboembolism with LMwHs and new 
anticoagulants
Andrew D Blann 
Chee w Khoo
University Department of Medicine, 
City Hospital, Birmingham, UK
Correspondence:   Andrew D Blann, PhD, 
FRCPath 
University Department of Medicine,  
City Hospital, Birmingham B18 7QH, UK 
Tel +44 121 507 5076 
Fax +44 121 507 5076 
email a.blann@bham.ac.uk
Abstract: As the risk factors for thrombosis are becoming better understood, so is the need for 
anticoagulation. The inherent difficulties with warfarin are such that a low-molecular-weight 
heparin (LMWH) is often the key therapeutic. However, there are several different species 
of LMWH available to the practitioner, which leads to the need for an objective guide. 
New agents are coming onto the marketplace, and these may supersede both warfarin and 
the heparins. The current report will review the biochemistry and pharmacology of differ-
ent LWMHs and identify which are more suitable for the different presentations of venous 
thromboembolism. It will conclude with a brief synopsis of new agents which may supersede 
warfarin and heparin.
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Introduction
The major common endpoint in most human disease is thrombosis and the major causes 
of arterial thrombosis (such as diabetes) have been established for decades. The risk 
factors for venous thromboembolism (VTE) (such as obesity and orthopedic surgery) 
are also now becoming well established and the penetrance of these factors in the 
pathophysiology of thrombosis is so strong that anticoagulation is often mandatory. 
Indeed, VTE is a frequent complication among hospital in-patients and contributes 
to longer hospital stays, morbidity, and mortality.1–4 Some VTEs may be subclinical 
and patients presenting with sudden pulmonary embolus (PE) or deep vein thrombosis 
(DVT) are common in acute medicine. Using ultrasonic Doppler and venographic 
techniques, DVT of the lower limb has been documented in half of all major lower 
limb orthopedic operations performed without antithrombotic prophylaxis, a quarter 
of patients with acute myocardial infarction (MI) and more than half of patients with 
acute ischemic stroke. Indeed, some risk factors are more likely to evoke a VTE than 
others (Table 1).
Accordingly, anticoagulation is demanded. However, the perfect anticoagulant 
(rapid mode of action and cessation, oral availability, minimal side effects, etc) does 
not exist. Instead, we have a crude poison with a long time to action and long half-life 
with a wide range of effect in different patients leading to difficulties in management 
(that is, warfarin), and an injectable agent with poor pharmacokinetics such that 
regular blood testing is required, and a risk of thrombocytopenia (that is, heparin).5 
More recently, some of the disadvantages of heparin have been reduced with the 
introduction of an improved preparation: low-molecular-weight heparin (LMWH).6,7 Vascular Health and Risk Management 2009:5 694
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However, there are several different species of LMWH 
available for the prevention of VTE, and all have slightly 
different properties and licenses for different risk situations. 
Fortunately, new anticoagulants are coming on to the market 
and it is conceivable that they will slowly take over from both 
warfarin and the heparins over the coming decade.
The objective of this communication is to review the role 
of the different LMWHs in the prevention of VTE. In order 
to do this the position of (unfractionated) heparin will be 
first be reviewed, following by an in-depth examination 
of LMWH. It will conclude with an examination of new 
anticoagulants.
Heparin
The modern era of heparin can be traced to 1880 with the 
description of anticoagulant preparations that evolved into 
heparin8–11 that ultimately became clinically useful.12–14 
Brinkhous and colleagues15 subsequently demonstrated the 
requirement of heparin for another substance in order for 
anticoagulation to be effected, a factor that we now recognize 
as antithrombin (formerly antithrombin III). Commercial 
heparin was thus ready for industrial/pharmacological 
scale production. By 1979, its value in prophylaxis for 
venous thrombosis, PE, and other possible problems were 
established.5 The laboratory potential of a more efficacious 
fraction of whole, unfractionated heparin, ie, LMWH, was 
recognized in 197916,17 and clinical note was made shortly 
afterwards.18,19
Mode of action
Heparin is a natural product present on the cell membrane, 
but when provided as a therapeutic drug, it is a mixture of 
glycosaminoglycans and polysaccharides composed of long 
chains of repeated disaccharide units (hexosamine and gluc-
uronic or iduronic acid), although the composition of different 
macromolecules vary markedly. In its whole, unfractionated 
form, with species of molecular weights ranging from 
3 to 30 kDa (although most is in the range 12–15 kDa), 
perhaps only one-third of a standard heparin preparation has 
anticoagulant activity.5 Heparin by itself is not an anticoagu-
lant: it is a co-factor in the activity of antithrombin, a 58 kDa 
single chain polypeptide synthesized in the liver.20
Heparin binding to specific sites on antithrombin induces 
a conformational change in the latter, exposing a site that 
binds serine proteases factor Xa, thrombin (IIa) (in approxi-
mately equal proportions) and, with less affinity, factors IXa, 
XIa, XIIa, kallikrein, plasmin, and C1-esterase, although 
almost all of its effects are against thrombin and factor Xa.5 
However, heparin fractions less than 18 monosaccharide 
units (3–4 kDa) do not enhance the inhibition of thrombin by 
antithrombin and probably act via factor Xa inhibition. The 
major inhibitor of coagulation, the effects of antithrombin 
are accelerated some 1000-fold in the presence of heparin. 
It follows, therefore, that special measures are required in 
subjects deficient in antithrombin (whether by genetics or 
excess consumption). In high doses, heparin also prolongs 
the bleeding time by inhibiting platelet aggregation in vitro21 
and may exert some effect on the endothelium,22 although 
it is unclear (and possibly academic) whether or not these 
influence clinical efficacy.
Clinical effectiveness
Due to variability of effect in different individuals, mostly 
due to complex pharmacokinetics (such as degree of binding 
to numerous proteins including, platelet factor 4, vitronectin, 
fibronectin and von Willebrand factor),23,24 laboratory monitor-
ing of the effects of heparin is necessary and can be followed 
with the relatively straightforward activated partial throm-
boplastin time (APTT), thrombin time, and to lesser extent, 
the prothrombin time. The APTT derives from the ability 
Table 1 Stratification of the risk factor for   VTE
Strong risk factors (increased risk 10)
Hip, pelvis or leg fracture, hip or knee replacement, major general surgery (eg, CABG), major trauma, spinal cord injury, hospital or nursing home 
confinement
Moderate risk factors (increased risk 2–9)
Arthroscopic knee surgery, central venous lines, malignancy (alone, 2–4 times, But with chemotherapy this rises to 4–6 times), congestive heart or 
respiratory failure, HRT, use of oral contraceptives, paralytic stroke, post-partum pregnancy, previous VTe, thrombophilia, neurological disease with 
extremity paresis, varicose veins at age 45, superficial vein thrombosis
Weak risk factors (increased risk 2)
Bed rest 3 days, immobility due to sitting (eg, prolonged car or air travel, wheelchair), increasing age, laparoscopic surgery (eg, cholecystectomy), 
obesity, ante-partum pregnancy, varicose veins at age 60
Abbreviations: CABG, coronary artery bypass graft; HRT, hormone replacement therapy;    VTe, venous thromboembolism.Vascular Health and Risk Management 2009:5 695
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of citrated plasma to clot an artificial ‘platelet’ substitute of 
phospholipids and other substances to which calcium has to 
be added: quality control is crucial as the quality of reagents 
can vary markedly.25 In practice, most clinicians aim for a 
degree of anticoagulation that prolongs the APTT by anything 
from 1.5 to 3 times that of normal, uncoagulated blood, ie, an 
APTT patient/control ratio of 1.5:3.0.4,26
The primary use of heparin has been, and continues to be, 
in the treatment and prophylaxis of VTE.5,26,27 As with aspirin, 
early crucial work was performed in the 1960’s with studies 
looking at the effect of heparin on PE and DVT.28,29 However, 
heparin is not absorbed from the gastrointestinal tract and 
so must be given intravenously or subcutaneously, with the 
former providing a more rapid effect. Subsequent trials not 
only confirmed the efficacy of this agent, but also showed that 
continuous intravenous infusion was frequently preferable to 
subcutaneous or intermittent infusions.30,31 One ‘typical’ trial 
reported a frequency of asymptomatic extension of DVT or 
PE of 8.2% of patients with proximal DVT taking heparin 
and oral anticoagulation compared to a frequency of 39.6% 
in those taking oral anticoagulants alone.32 There was also a 
reduction in the report of symptomatic events (6.7% versus 
20%), but no difference in hemorrhagic complication (3% 
versus 5%). In practice, until recently, hospital treatment of, 
and prophylaxis against, VTE, generally began with heparin, 
moving oral anticoagulants following discharge, for varying 
periods up to six months.33
Clinical side effects
As with aspirin, the major problem with heparin is in dose-
dependent excess bleeding. Early commentaries reported a 
rate of hemorrhagic complications of up to 30%.34 However, 
a later review reported an incidence of 6.8% in patients given 
continuous infusion and 14.2% in patients given intermit-
tent intravenous injections,5 emphasizing four important 
variables: dose, patient’s anticoagulant response, method 
of administration, and other patient-related factors such as 
renal failure or chronic alcohol use. Gallus and colleagues35 
reported an incidence of major bleeding of 11% in high-risk 
patients, compared to 1% in low-risk patients.
Surprisingly, heparin-induced thrombocytopenia 
(HIT; generally platelet count 140,000 cells/µL, and 
reversible) has been described for 50 years,36 with two 
forms (nonimmune and immune [often an immunoglobulin 
G [IgG] targeting a heparin/platelet factor 4 complex]) 
being recognized.37 When the platelet count falls, especially 
if it falls from normal to less than 100,000 cells/µL, 
cessation is mandatory and alternate anticoagulant cover 
(eg, argatroban)26,38 is necessary. Curiously, 0.4% of patients 
with HIT suffer arterial thrombosis (that may follow platelet 
aggregation in vivo) or venous thrombosis (that may result 
from heparin resistance caused by the neutralizing effect 
of the heparin-induced release of platelet factor 4). These 
events may be related to the generation of thrombin,39 and 
also to platelet activation by heparin.21,40 If present, HIT is 
likely to be apparent 3 to 15 days after initiation (such that 
a platelet count is advised on days 3–5), but may also occur 
very rarely within hours, with the platelet count returning to 
normal within four days of discontinuation.41 Rates of HIT 
vary between 0.1% and 3%.26,37,42
Other uncommon side effects of heparin (especially in 
long-term and high-dose use) include fractures and osteopenia, 
hyperkalemia, elevations in liver enzymes, skin necrosis 
at the site of administration, alopecia, hypersensitivity, 
priapism, and hypoaldosteronism.5,26,43–48 Thus, despite the 
proven safety and effectiveness of continuous infusions 
of heparin, its limitations and adverse side effect profile, 
unpredictable pharmacokinetic response, daily laboratory 
monitoring with dose adjustments, and requirement for 
hospitalization leaves room for alternatives. One such 
alternative is a low-molecular-weight variant of the standard 
(unfractionated) heparin preparation.
Low-molecular-weight heparin
The laboratory demonstration of a more efficacious fraction 
of whole, unfractionated heparin, ie, LMWH,16–19 has 
ushered in a new era of anticoagulation. LMWH can be 
manufactured from unfractionated heparin by diverse routes, 
such as benzylation with alkaline hydrolysis, nitrous acid 
depolymerization or digestion, heparinase digestion, and 
isoamyl nitrate digestion. Each provides a different LMWH 
with mean molecular weights varying from 4371 Da to 
5866 Da, so that each has different pharmacokinetics and 
activities.49–51 However, there are common class advantages 
over unfractionated heparin (Table 2), most of which address 
mode of action and side effects. Broadly speaking, compared 
to unfractionated heparin, LMWH has a longer subcutaneous 
half-life and therefore has potential for outpatient use, a more 
predictable anticoagulant response requiring less monitoring, 
and has better antifactor Xa effect.
Building on early trials,18,19 several large studies have 
unequivocally demonstrated the value of LMWH in the initial 
treatment of DVT.52–54 Lensing and colleagues52 described 
a recurrence rate of 3.1% in patients on LWMH compared 
to 6.6% (p  0.01) in those on standard heparin, with 0.8% 
and 2.8% (p  0.005) suffering a major bleed, respectively, Vascular Health and Risk Management 2009:5 696
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which was confirmed by other analyses. However, later 
trials55,56 failed to find a difference in efficacy between the 
two types of heparin with equivalence of adverse events. 
Interestingly, these meta-analyses also reported a lower 
mortality with LWMH due to causes unrelated to VTE in the 
patients particularly with cancer. A subsequent more formal 
meta-analysis of 629 cancer patients did indeed demonstrate 
a benefit in three-month mortality for LMWH versus unfrac-
tionated heparin.57 While this is an unsought for endpoint 
and therefore of questionable value, there is nevertheless 
good mechanistic evidence for this benefit.58 The value of 
LMWH compared to unfractionated heparin now extends 
to prevention of thrombosis in general surgery, orthopedic 
surgery, hip fracture, multiple trauma, and neurosurgery,51 
whilst efficacy and safety issues in medical patients have 
been addressed.59
Apart from its clinical effectiveness and better side effect 
profile, a further advantage of LMWH is in home use by 
appropriate patients with DVT who are not severely ill.60,61 
In both studies, LMWH administered subcutaneously twice-
daily was compared with standard continuous infusion in 
hospital. Both reported no significant difference in recurrence 
of thromboembolism with similar rates of bleeding. Those 
on LMWH in the study of Levine and colleagues60 remained 
in hospital for a mean of 1.1 days, suffering 13 embolic 
events, compared to 6.5 days for those on unfractionated 
heparin, with 17 events, of which two were fatal. The health 
economics of these figures is apparent, even after adjustment 
for the higher costs of the LMWH. The study of Koopman and 
colleagues61 included quality of life data: overall, there was 
no difference between the LMWH and unfractionated heparin 
groups, but those on LMWH reported better physical activity 
and social functioning at weeks 1–2. Data demonstrating the 
superiority of LMWH compared to unfractionated heparin 
(eg, shorter time to effective anticoagulation and more days 
of effective anticoagulation) continues to be published.62
Whilst the weight of literature focuses on (unprovoked) 
DVT and PE, LMWH is also effective in those with conditions 
predisposing to VTE, such as cancer,63–65 although more data 
on other groups, such as the obese and those in renal failure or 
with thrombophilia66–69 is needed and these are slowly becom-
ing available. However, despite the weight of literature on 
LMWH, questions and doubts remain. For example, Knight 
and colleagues conclude that heparins may, in some circum-
stances, be pro-thrombotic.70 Thus there remains scope for 
more efficacious, yet safe, anticoagulants.71
Which LMWHs are available?
In the United Kingdom, pharmaceutical practice in NHS 
hospitals is dominated by the British National Formulary 
(BNF).72 This book, also available online, is updated each 
six months, and lists all government-approved pharmaceutical 
agents and their licensed indications. It follows that doses 
and guidelines may differ in other countries, and that doses 
in prefilled syringes may also differ. Four types of LMWH 
are described In issue 57 of the BNF. These are (in alphabetic 
order) bemiparin, dalteparin, enoxaparin, and tinzaparin. 
All are given subcutaneously and regimes are markedly 
different for prophylaxis of VTE versus treatment of VTE. 
Furthermore, all have numerous cautions and contraindica-
tions. Principal among these is the need to refer to renal func-
tion because several agents are cleared by this organ so that 
defective clearance effectively leads to higher biologically 
active levels and thus a risk of overanticoagulation, which 
may lead to hemorrhage. An additional concern is the liver, 
as failure of this organ to synthesize key coagulation proteins 
may also lead to a risk of hemorrhage. Other LMWHs are 
available and include nadroparin and certoparin.
Bemiparin
This agent is licensed for the prophylaxis of DVT. For patients 
at moderate risk (for the definition of risk, see Tables 4 and 5 
and the discussion to come), the recommended dose is 
2500 units two hours before or six hours after surgery, 
Table 2 Differences between low-molecular-weight heparin and 
unfractionated heparin48–51




Mean molecular weight (kDa) 5 15
Saccharide units 13–22 40–50
Anti-Xa/Anti-iia activity 2:1 to 4:1 1:1
Platelet inhibition + + + + + +
inhibited by PF4 No Yes
Bioavailability 92%–100% 30%–50%
Half-life (hours)
  intravenous 2 1
  Subcutaneous 4 2
endothelial binding No Yes
Dose-dependent clearance No Yes
Mode of clearance Kidney Liver/kidney
Frequency of HiT Low (eg, 0%*) High (eg, 2.7%42)
Frequency of osteoporosis Low High
Monitoring Anti-Xa assay Routine APTT
Abbreviations: HiT,  heparin-induced thrombocytopenia; PF4, platelet factor 4;   
  APTT,  activated partial thromboplastin time.Vascular Health and Risk Management 2009:5 697
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then 2500 units every 24 hours for 7–10 days. High-risk 
patients should receive 3500 units two hours before to 
six hours after surgery, then 3500 units every 24 hours for 
7–10 days. Treatment of DVT (with or without PE) is likely to 
be 115 units/kg every 24 hours for 5–9 days and until adequate 
oral anticoagulation (inevitably warfarin) is established.
Dalteparin
This agent is licensed for additional indications. For 
prophylaxis of DVT in surgical patients at moderate 
risk, 2500 units 1–2 hours are given before surgery, then 
2500 units every 24 hours for 5–7 days or longer. High-risk 
patients are also likely to require 2500 units 1–2 hours before 
surgery, but then 2500 units 8–12 hours later (or 5000 units 
on the evening before surgery, then 5000 units on the follow-
ing evening), with 5000 units every 24 hours for 5–7 days 
or longer (five weeks in hip replacement). For prophylaxis 
of DVT in medical patients, 5000 units are given every 
24 hours. Treatment of DVT and PE in adults is dose-adjusted 
to body weight less than 46 kg, 7500 units/day, 46–56 kg 
10,000 units/day, 57–68 kg, 12,500 units/day, 69–82 kg, 
15,000 units/day, and body weight over 83 kg 18,000 units/day, 
with oral anticoagulant until the international normalized 
ratio (INR) is in the therapeutic range (which may take up 
to seven days). Monitoring of the effect of the LMWH is not 
usually needed but if so is by antifactor Xa assay.
There is an unlicensed indication for dalteparin for the 
treatment of VTE in pregnancy. This calls for dose-adjusted 
injections based on early pregnancy body weight: under 
50 kg, 5000 units twice daily; 50–70 kg, 6000 units twice 
daily; 70–90 kg 8000 units twice daily, and body weight over 
90 kg, 10,000 units twice daily. If called for, blood should be 
taken for monitoring 3–4 hours after a dose, and ideally the 
result will be in the range or 0.5 to 1 unit/mL of antifactor 
Xa activity. Monitoring is generally not required for once-
daily treatments. Notably, this desired range is higher than 
that for prophylaxis of a VTE, which is 0.1–0.3 antifactor 
Xa units/mL. Daltaparin is also licensed for use in acute 
coronary syndromes, which are effectively unstable coronary 
artery disease of ST and non-ST elevation MI. The weight-
adjusted dose is 120 units/kg every 12 hours (up to 10,000 units 
twice daily) for up to eight days. Beyond this period, such as 
if awaiting invasive procedures, then the dose may change. 
Dose also varies by sex. For women weighing less than 80 kg 
and men less than 70 kg, the recommended dose is 5000 units 
every 12 hours. Above this weight the dose is 7500 units every 
12 hours. This proceeds until the day of the procedure for a 
maximum of 45 days.
enoxparin
This agent also has multiple indications. For prophylaxis of DVT 
in surgical patients at moderate risk, the recommended dose is 
20 mg (2000 units) about two hours before surgery then 20 mg 
(2000 units) every 24 hours. High-risk patients (such as those 
undergoing orthopedic surgery) will need 40 mg (4000 units) 
12 hours before surgery and repeated every 24 hours for 
7–10 days. Medical patients have the same regime but for at least 
six days and until ambulant to a maximum of 14 days. Treatment 
of either forms of VTE calls for 1.5 mg/kg (150 units/kg) every 
24 hours, usually for at least five days and until oral anticoagu-
lation is effective (generally INR 2–3). In unstable angina and 
non-ST-segment elevation MI, 1 mg/kg (100 units/kg) every 
12 hours usually for 2–8 days (minimum two days) is recom-
mended, and there is also an unlicensed indication for the treat-
ment of VTE in pregnancy: early pregnancy body weight under 
50 kg, 40 mg (4000 units) twice daily; body weight 50–70 kg, 
60 mg (6000 units) twice daily; body weight 70–90 kg, 80 mg 
(8000 units) twice daily; body weight over 90 kg, 100 mg 
(10 000 units) twice daily.
Tinzaparin
For the prophylaxis of DVT in general surgery, the recom-
mended dose is 3500 units two hours before surgery, then 
3500 units every 24 hours for 7–10 days. In orthopedic 
surgery, it may be dose-adjusted: 50 units/kg two hours 
before surgery, then 50 units/kg every 24 hours for 7–10 days 
or 4500 units 12 hours before surgery, then 4500 units every 
24 hours for 7–10 days. The treatment of DVT and PE calls 
for 175 units/kg once daily for at least six days and until 
adequate oral anticoagulation, eg, with warfarin, is estab-
lished. Once more, there is an unlicensed indication of VTE 
in pregnancy, which is 175 units/kg once daily.
Choice of LMWH
The previous section listed the different clinical scenarios 
that each LMWH may be used for. Leaving aside economic 
considerations, the practical level issues of ease of 
prescribing, dose adjustment, and timing of dose seem 
relevant. The practitioner must also be fully aware of cautions, 
contraindications, and other caveats of each particular LMWH 
which may be relevant in a particular patient. Irritatingly, there 
are few (if any) good, well powered trials comparing one 
LMWH with another. In almost all such trials the (generally 
inferior) comparator is unfractionated heparin.52–59 All other 
factors being equal, due to pressures on individual hospital 
pharmacies, many opt for a LMWH that has the broadest 
range of clinical applications (Table 3).Vascular Health and Risk Management 2009:5 698
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Use of LMWHs in practice
Fortunately, there are numerous guidelines for the use of 
LMWHs for prophylaxis in various settings such as in 
obstetrics and gynecology, and after surgery, and many are 
available free and online.73–79 Practice in surgery in the UK 
is dominated by guidelines from the National Institute for 
Health and Clinical Excellent (NICE).79 However, other 
comprehensive guidelines with more international appeal 
such as those of the American College of Chest Physicians73 
are widely used. Unsurprisingly, there is often considerable 
agreement between these guidelines. The NICE document 
recommends that all patients about to undergo surgery should 
be assessed to identify their risk factors for developing VTE, 
which can be assessed by a scoring system. Once a particular 
patient’s risk of VTE has been assessed (Table 4), then the 
risk afforded by their surgery must also be assessed (Table 5). 
Clearly, some operations are more likely to promote VTE 
than other, and the most risky include orthopedic surgery. 
Once any cautions and contraindications have been addressed 
(such as allergy, HIT, hepatic or renal impairment), then 
treatment may be given (Table 6). The duration of treatment 
varies, bearing in mind that some patients may transfer to 
warfarin, especially if they have concurrent long-standing 
risk factors such as cancer. Notably, NICE recommends 
treatment for four weeks after certain orthopedic proce-
dures.79 The section above applies to the prevention of a 
VTE. However, once a patient actually has a DVT or PE, then 
a different dosing regime is called for, which is effectively 
more anticoagulants (Table 7).
Fondaparinux
Technically, this agent may not be a ‘heparin’ or even 
a ‘LMWH’, but it certainly does inhibit the coagulation 
pathway in the same manner. Marketed as Arixtra® by 
GlaxoSmithKline, fondaparinux is a novel, selective and 
reversible Xa-inhibitor, although based on the structure 
of heparin, is different from both heparin and LMWH. 
Accordingly, unlike heparin and LMWH, it has minimal, 
if any, activity against thrombin.80,81 Pharmacokinetics 
are characterized by a 100% bioavailability by subcutane-
ous route, lack of biometabolism, urinary excretion and a 
relatively long plasma half-life of 14–21 hours which per-
mits once-daily injection. There is a rapid onset of action, 
with a peak activity reached in two hours. No interactions 
with aspirin, warfarin, or digitoxin have been noted. 
Fondaparinux, like LMWHs, does not affect the prothrombin 
Table 3 indication for the use of low-molecular-weight heparins
  Bemiparin Dalteparin Exonaparin Tinzaparin
Prophylaxis of   VTe Yes Yes Yes Yes
Treatment of   VTe Yes Yes Yes Yes
Treatment of   VTe in pregnancy 
(unlicensed)
No Yes Yes Yes
Prophylaxis of   VTe in acute 
coronary syndromes
No  Yes  Yes  No 
Notes: Data was obtained from BNF.72 Referral in practice is essential, especially in view of cautions and contraindications which may be low-molecular-weight 
heparin-specific.
Table 4 Risk factors for VTe
Risk factors (Score 1) Risk factors (Score 2) Risk factors (Score 3)
Age 60 estrogen-containing pill immobile (72 hours)
Obesity (BMi  30) HRT History of DVT/Pe
iHD, CCF or previous stroke Known thrombophilic conditions
Significant COPD Malignancy
extensive varicose veins Sepsis
Inflammatory bowel disease Known family history in two relatives  
(at least one first degree)
Nephrotic syndrome Post-partum
Myeloproliferative disorders Pregnancy  
Abbreviations: BMi, body mass index; COPD, chronic obstructive pulmonary disease; CCF, congestive cardiac failure; DVT, deep vein thrombosis; HRT, hormone replacement 
therapy; iHD, ischemic heart disease; Pe, pulmonary embolism.Vascular Health and Risk Management 2009:5 699
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time (PT) and has very weak effects on APPT but its activity 
can be determined by specific anti-Xa assays, if necessary. 
Thrombocytopenia (platelet count 100 × 109/L) occurs 
even less commonly than with LMWH.
Use of fondaparinux has been approved by NICE as 
an alternative to LMWH in certain types of surgery, such 
as orthopedic.79 In this setting the prophylaxis regime 
recommended by the BNF72 calls for 2.5 mg six hours 
before surgery then 2.5 mg daily for 5–9 days (longer after 
hip surgery), and the same dose for thromboprophylaxis in 
medical patients usually for 6–19 days. For treatment of  VTE, 
the recommended weight-adjusted dose is 5 mg (if weight 
under 50 kg), 7.5 mg (50–100 kg), or 10 mg (over 100 kg) 
every 24 hours and generally for five days and until oral 
anticoagulation is adequate.
New anticoagulants
Although LMWHs are very effective agents, they still carry 
some problems such as a residual risk of heparin-induced 
thrombocytopenia and reliance of parenteral introduction. 
These, and other problems, are being overcome with the 
introduction of new agents. Some operate directly against 
thrombin, others target coagulation factor Xa.82–86
Direct thrombin inhibitors
Dabigatran etexilate (marketed as Pradaxa® by Boehringer 
Ingelheim GmbH) is the first in a new class of anticoagulant 
that works by directly inhibiting thrombin. It possesses 
various qualities which make it potentially an attractive 
and promising novel oral anticoagulant with its predict-
able pharmacokinetics and pharmacodynamics.87 The drug 
has rapid absorption (within two hours) and distribution 
with estimated half-lives of 8–10 hours and 14–17 hours 
for single and multiple dose administrations, respectively. 
Nearly 80% of dabigatran etexilate is excreted unchanged 
by the kidneys with average bioavailability of 6.5%, hence 
high doses are required to maintain adequate plasma 
concentrations. Of note, the drug absorption is reduced 
by 20%–25% if patients are concurrently on proton pump 
inhibitors. Phase II and III clinical trials have been conducted 
assessing dosages, efficacy, and tolerability in numerous 
indications such as prevention of secondary VTE, DVT, 
stroke, and embolism due to atrial fibrillation (AF).88–93
In the BISTRO I study,88 dabigatran etexilate demonstrated 
an acceptable safety therapeutic profile with doses ranging 
between 12.5 mg and 300 mg twice daily in patients under-
going elective total hip replacement. Historically, the latter 
is one type of surgery where more than 50% of patients 
develop VTE in the absence of thromboprophylaxis. 
Subsequently, the BISTRO II study89 compared four dif-
ferent doses of dabigatran etexilate with enoxaparin, with 
a significant reduction of VTE events in total hip or knee 
replacement patients receiving 150 mg twice daily, 300 mg 
once daily, and 225 mg twice daily. There is also data on 
stroke prevention in AF. The PETRO study90 was conducted 
in 502 participants randomized to receive different dozes of 
dabigatran alone or in combination with aspirin (81 mg or 
325 mg) or open-label warfarin. This clinical study found no 
serious liver toxicity with only a small fraction of patients 
(0.9%) observed to have raised aminotransferase levels and 
also justified dose selection for subsequent trials.
In March 2008, the regulatory authorities of the European 
Union approved the use of dabigatran etexilate for DVT 
Table 5 Additional risk factors for surgical inpatients
Score Surgical procedure
4 Major trauma; eg, lower limb fractures
4 Major joint replacement
4 Surgery for fractured neck of femur
3 Thoracotomy or abdominal surgery involving mid-line 
laparotomy
3 Total abdominal hysterectomy; including laparoscopic assisted
2 intraperitoneal laparoscopic surgery lasting 30 minutes
2 Vascular surgery (not intra abdominal)
1 Surgery lasting 30 minutes
0  Surgery lasting 30 minutes
Note: The total risk score will give an initial guide to therapy, although low-molecular-
weight heparin may not be appropriate for all patients.
Table 6 Application of risk assessment for the use of low-molecular-weight heparin (LMwH)
Low risk Score 0 or 1  Moderate risk Score 2 or 3  High risk Score 4
•  early ambulation 
•  Consider GeCS
•  GeCS 
•  Low dose LMwH od for surgical patients 
•  High dose LMwH od for medical patients
•  GeCS 
•  High dose LMwH od (max. 14 days for medical in-pts) 
•    Surgical patients – consider iPC in theatre plus high dose LMwH
Note: For male patients 57 kg and female patients 45 kg, caution may be needed regarding the dose of LMwH prescribed.
Abbreviations: iPC, intermittent pneumatic compression; GeCS, graduated elastic compression stockings; od, once daily.Vascular Health and Risk Management 2009:5 700
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prevention postelective total hip or knee replacement surgery. 
This was followed by approvals from Health Canada in 
June 2008. Dabigatran etexilate has been available in UK 
since April 2008 and was subsequently included in the DVT 
prevention guidance issued by NICE five months later.94,95 
The BNF recommended daily doses for VTE prevention 
in total knee replacement surgery is 110 mg (elderly over 
75 years, 75 mg) 1–4 hours after surgery, then 220 mg 
daily (elderly over 75, 150 mg) for nine days. For total hip 
replacement surgery, the same dose is recommended but 
it should continue for 27–34 days. As is common practice 
with almost all anticoagulants, patients with moderate renal 
impairment (glomerular filtration rate 30–50 mL/min) require 
reduced dosages.
Factor Xa inhibitors
These agents reversibly block free factor Xa and that factor 
Xa that is bound to platelets within the prothrombinase 
complex. Two oral factor Xa inhibitors are currently under 
various stages of clinical development and are close to 
potential clinical application. Rivaroxaban (marketed as 
Xarelto® by Bayer Schering Pharma AG) is the first selective 
oral direct factor Xa inhibitor advanced to phase III clinical 
trials. It has favorable pharmacokinetic characteristics with 
a bioavailability of 60%–80%. Rivaroxaban achieves peak 
plasma levels in three hours and has a half-life of nine hours 
in healthy, young subjects and about 12 hours in elderly 
subjects. However, the drug has been tested for clinical use 
only on a once-daily basis. Rivaroxaban is metabolized by 
the liver via CYP3A4 with up to two-thirds of the drug being 
eliminated by the kidneys. The use of rivaroxaban in patients 
with renal impairment has to be cautious because of its renal 
clearance. It does not significantly interact with platelet func-
tion in preclinical studies, where it demonstrated an excellent 
correlation between its plasma levels and achieved clotting 
times, while the bleeding risk was comparable to that of 
enoxaparin.96,97
The phase III clinical trials, the RECORD Studies, 
were designed to look at the effectiveness of rivaroxaban in 
the prevention of VTE in patients undergoing hip or knee 
surgery. The RECORD I and RECORD III trials revealed 
higher effectiveness of rivaroxaban compared to enoxaparin 
in VTE prevention following orthopedic surgery surgery, 
whilst the RECORD II study provided evidence that pro-
longed administration of rivaroxaban had additional clinical 
benefits compared to short-term therapy.98–100 The utility of 
rivaroxaban for VTE treatment was assessed in two phase II 
studies which showed that rivaroxiban had similar efficacy 
when compared with enoxaparin/warfarin in the treatment 
of VTE.
In the ODIXa-DVT study, the incidence of major and 
minor bleeding increased with escalating doses of rivaroxiban 
(range of 5.0% to 11.6%) as compared with patients treated 
with enoxaparin/warfarin (6.3%).101 In the EINSTEIN-DVT 
study, the incidence of clinically relevant bleeding occurred 
in 2.2%–6.0% of patients in rivaroxaban groups and in 8.8% 
of patients in heparin/warfarin group, with no significant 
dose response for bleeding.102 In these two studies, no 
dose-efficacy relationship with rivaroxaban treatment was 
observed. However, the dose-dependent increase in the risk 
of bleeding was reported in the ODIXa-DVT study indicating 
that a twice-daily regimen for rivaroxaban might increase 
risk of bleeding. Nonetheless, the results of these two studies 
had supported the safety and efficacy of rivaroxaban in the 
treatment of DVT. Based on these results, further phase III 
randomized trials of rivaroxaban for the treatment of DVT 
and for the prevention of stroke in AF (ROCKET-AF) with 
20 mg once-daily are undergoing. Rivaroxaban was been 
assessed by NICE,103 who have recommended it as an option 
for the prevention of VTE in adults having elective total 
hip replacement surgery or elective total knee replacement 
surgery. The initial dose, subject to normal hemostasis and 
reflective of additional risk factors, should be 10 mg within 
6–10 hours after surgery, then for two weeks in knee surgery 
or five weeks in major hip surgery.
Apixaban is a highly selective and potent inhibitor of 
factor Xa at advanced clinical development. It has a small 
molecular weight, with a bioavailability of more than 50% 
Table 7 Use of low-molecular-weight heparins in prophylaxis versus treatment in an 80 kg patient
  Bemiparin Dalteparin Enoxaparin Tinzaparin
Prophylaxis in  
moderate-risk surgery
2,500 units 2,500 units 20 mg/2,000 units 3,500 units  
(general surgery)
Prophylaxis in  
high-risk surgery
3,500 units 5,000 units 40 mg/4,000 units 4,000–4,500 units 
(orthopedic surgery)
Treatment of   VTe 9,200 units 15,000 units 120 mg/12,000 units 14,000 units
Notes: Data obtained from BNF.72 Practitioners must consult this source or their own local guidelines before acting.Vascular Health and Risk Management 2009:5 701
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and half-life of between nine and 14 hours. Apixaban has 
fixed twice-daily dosing and is metabolized in the liver 
via CYP3A4, with about 25% excreted by the kidneys and 
the remainder by intestinal excretion.104 It has been shown 
to be safe and well tolerated in initial testing in volunteers 
and its anticoagulant effects closely correlated to plasma 
concentration of the drug. In the phase II APROPOS trial 
apixaban prevented more cases of VTE and death after total 
knee replacement than enoxaparin, but the risk of bleeding 
correlated with drug dose.105 In a relatively small Botticelli-
DVT trial (520 patients with acute symptomatic DVT), 
apixaban demonstrated effectiveness in the prevention of 
recurrent VTE similar to conventional therapy with LMWH 
followed by warfarin (target INR 2.0–3.0). The principal 
safety outcome (composite of major and clinically relevant, 
nonmajor bleeding) occurred in 7.3% of the apixaban-treated 
patients versus 7.9% of patients with reference treatment.106
Another direct thrombin inhibitor, betrixaban, is being 
trialed. It has a small molecular weight, with an oral bioavail-
ability of 47% and half-life of 19 hours, and is eliminated 
via intestinal excretion. A randomized phase II clinical trial, 
the EXPERT study, investigated the safety and efficacy 
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of betrixaban in comparison with enoxaparin for VTE 
prevention in patients undergoing total knee replacement 
surgery. More than 200 patients were randomized to either 
betrixaban (15 or 40 mg twice daily) or enoxaparin (30 mg 
twice daily). Betrixaban demonstrated antithrombotic activity 
and appeared well tolerated in knee replacement patients at 
the doses studied.107
Conclusions
In the UK, government initiatives have pushed anticoagulation 
center-stage in many aspects of medical and surgical 
care.108,109 The vast weight of prevention and treatment of 
VTE falls to the management of warfarin and LMWHs, with 
fondaparinux gaining use. However, the last few years has 
seen the development of new oral anticoagulants that may 
take over from currently established agents,110 and for which 
government bodies are releasing guidelines.78,79,94,103 It seems 
likely that future practice will see the increasing use of novel 
oral anticoagulants.
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